In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Abnormal echocardiographic findings in cancer patients before chemotherapy

Session Poster session 5

Speaker Oscar Gonzalez Fernandez

Event : EuroEcho 2015

  • Topic : other
  • Sub-topic : Other
  • Session type : Poster Session

Authors : O Gonzalez Fernandez (Madrid,ES), C Alvarez Ortega (Madrid,ES), R Mori Junco (Madrid,ES), J Caro Codon (Madrid,ES), P Meras Colunga (Madrid,ES), I Ponz De Antonio (Madrid,ES), T Lopez Fernandez (Madrid,ES), S Valbuena Lopez (Madrid,ES), M Moreno Yanguela (Madrid,ES), JL Lopez-Sendon (Madrid,ES)

Authors:
O Gonzalez Fernandez1 , C Alvarez Ortega1 , R Mori Junco1 , J Caro Codon1 , P Meras Colunga1 , I Ponz De Antonio1 , T Lopez Fernandez1 , S Valbuena Lopez1 , M Moreno Yanguela1 , JL Lopez-Sendon1 , 1University Hospital La Paz, Cardiology - Madrid - Spain ,

Citation:
Eur Heart J Cardiovasc Imaging Abstracts Supplement ( 2015 ) 16 ( Supplement 2 ), ii200

Introduction: Cancer patients receiving chemotherapy and radiation therapy (RT) present an increased risk of developing cardiovascular complications. Different studies correlate abnormal echocardiographic findings (AEF), as well as the presence of cardiovascular risk factors (CVRF) with cardiotoxicity. Previous series show a high prevalence of AEF before treatment. The purpose of our study is to analyze the prevalence of baseline AEF and CVRF before cardiotoxic treatment.

Methods: Patients from GECAME and CARDIOTOX registries were included. A TTE was performed between august 2010 and april 2015 before starting chemotherapy.

Results: A total of 576 patients were included, mean age was 55.3 ± 14.2, 83% female. Tumor location was: 56.3% breast, 26% lymphoma. 11.6% had previous cancer, 5.9% previous chemotherapy and 4.5% RT. Regarding CVRF, 21.5% had hypertension, 24.9% dyslipidemia, 7.1% diabetes and 26% current smoking. Medium left ventricular ejection fraction (LVEF) was 63.6 ± 6.2%, 2.2% of patients had a LVEF<53%. Medium global longitudinal strain (GLS) was -18.7 ± 2.8, 46.1% had a GLS>-19% and 4.6% >-15%. TAPSE<16mm occurred in 0.8% of patients. Lateral E/E'ratio was>15 in 4.4%. The most common AEF was left atrial enlargement (LAE), present in 23.1%. We found significant differences in left ventricular dysfunction (LVEF<53%), GLS>-19, lateral E/E'ratio>15 and LAE according to age, more prevalent in patients older than 60. Previous cancer and chemotherapy associate a higher prevalence of left ventricular dysfunction, as well as hypertension and diabetes.

Conclusions: Elderly, previous oncologic history and CVRF associate a higher prevalence of AEF. Young patients without CVRF may not require a TTE before chemotherapy, allowing a concentration of resources to monitor cardiotoxicity while treatment.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are